Results 101 to 110 of about 75,247 (182)

Availability and Pricing of Orthobiologic Knee Injections Vary by Practice Type but Not by Community Socioeconomic Vulnerability in Suburban New York

open access: yesArthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To assess the availability, price transparency, and pricing of platelet‐rich plasma (PRP), bone marrow aspirate concentration, and stem cell injections for knee osteoarthritis (OA) among orthopaedic sports medicine (OSM) practices and alternative clinics in suburban New York and to evaluate the impact of the economic status of a population on ...
Tracy M. Tauro   +6 more
wiley   +1 more source

Optimizing merchant compliance: A system for product specific rule extraction using NLP. [PDF]

open access: yesMethodsX
Khewalkar A   +5 more
europepmc   +1 more source

Gender Equity in Rheumatology Research: Global Analysis of Authors

open access: yesArthritis &Rheumatology, EarlyView.
Objective To investigate gender representation of authors in rheumatology research over the last decade. Methods Using metadata from original and review articles published between 2015 and 2024 in SCImago top two quartile (Q1, Q2) rheumatology journals, author gender was classified using two public databases.
Michael Girdwood   +7 more
wiley   +1 more source

Non‐melanoma skin cancer risk with Janus kinase inhibitors compared to interleukin‐6 receptor inhibitors in rheumatoid arthritis: results from a national cohort study

open access: yesArthritis &Rheumatology, Accepted Article.
Background Non‐melanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with Janus kinase inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Method This study used data from the British Society for Rheumatology Rheumatoid Arthritis Register (BSRBR‐RA) linked
Zixing Tian   +8 more
wiley   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease   +20 more
wiley   +1 more source

Risk of Cancer according to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study from the French Health Insurance Database

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy